DEC 17, 2016 08:47 AM PST

Deficiency of Two Opposing Enzymes Spurs Liver Cancer

WRITTEN BY: Xuan Pham

If a cancer is caused by the over-activation of proteins that enhance growth, then blocking these enzymes should stunt the tumor. Yet, in liver cancer, drugs that inhibit growth enzymes do not seem to slow the cancer growth. And the most recent research suggests that cancer biology is more complex than previously thought.

"When it comes to liver cancer, I think we've been making strategic mistakes," said Gen-Sheng Feng, professor at the University of California, San Diego, and the study’s senior author. "In cancer development, we always thought about two distinct families of enzymes -- one promotes cancer, one inhibits it.”

Indeed, this line of thinking has led to the creation of drugs that, for the most part, do one or the other. That is, they either block the over-active pro-cancer enzymes or stimulate the activity of anti-cancer proteins. “Many drugs have been developed to block the cancer-promoting pathways, but we and others are now finding that many classical pro-cancer proteins are actually inhibitors,” said Feng. This explains why the intended consequences for anticancer drugs don't always work.

To better understand the mechanism behind why cancer drugs fail in liver cancer, the team honed in on the balance of tumor-suppressor genes versus those that promote tumor growth in a mouse model. They found that mice that lacked both types of proteins are, paradoxically, most susceptible to liver disease and cancer.

In particular, the two opposing cancer proteins were identified as Shp2 and Pten. Shp2 is well-characterized as a tumor-promoting protein, while Pten is a known tumor-suppressing protein. Yet, mice with a loss of both of these proteins had the largest and most prominent tumor formation in the shortest amount of time.

"So the roles of tumor-promoting and tumor-suppressing enzymes are not as simple as we thought," Feng said. "This also explains many unwanted side effects with drugs that target these enzymes. Their consequences can differ depending on cell type."

Feng’s team theorized that loss of the two enzymes triggered uncontrolled inflammation and fibrosis in the liver, which helped promote tumor formation. Interestingly, when they analyzed human liver cancer samples, the team found a similar pattern – those with low or deficient levels of SHP2 and PTEN typically had the poorer prognoses.

"Liver cancer is more complicated than we thought. These pathways, when over-activated, stimulate tumor development, but so does inhibiting them," Feng said. "That's why we can't rush to conclusions like we have in the past. But now that we have a good model that mimics the human pathogenic process and we can use that to work out the mechanisms that lead to liver disease and cancer, and search for novel drug targets."

Additional sources: UC San Diego Health

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 19, 2019
Cancer
OCT 19, 2019
Can soda give me cancer?
We all know that excess consumption of sugary drinks like soda and 100% fruit juices are not good for us. The high quantities of sugar in these beverages h...
OCT 19, 2019
Cancer
OCT 19, 2019
Could electromagnetic fields treat metastatic triple-negative breast cancer?
New research published in Communications Biology suggests that electromagnetic fields are capable of stopping the metastasis of some breast cancer cells. I...
OCT 19, 2019
Cancer
OCT 19, 2019
The role of sleeper cells in metastasis
New research published in the journal Nature Communications aims to explain why some breast cancers recur following cancer treatment. According to col...
OCT 19, 2019
Cancer
OCT 19, 2019
Early onset colorectal cancer on the rise
New research from the American Cancer Society and recently published in Gut shows that colorectal cancer in young adults is on the rise in high-income coun...
OCT 19, 2019
Cancer
OCT 19, 2019
Handheld device detects skin cancer
I can’t be the only one who has ever looked at a suspicious freckle and wondered, “Could this be skin cancer?” Of course, when 9,500 Amer...
OCT 19, 2019
Cancer
OCT 19, 2019
One third of women don't take advantage of free cancer screenings
Have you ever received a cancer screening? If you haven’t, you’re not alone. New research from King's College London and Queen Mary Univers...
Loading Comments...